Gilead and Merck today (Tuesday, July 21) announced new results from the Phase 3 ISLEND-1(NCT06630286) andISLEND-2(NCT06630299) trials evaluating the treatment responses of people living with HIV with virological suppression who switched from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) or a standard of care oral daily antiretroviral regimen to an investigational once-weekly single-tablet regimenof islatravir 2 mg/lenacapavir 300 […]